Olaparib, AZD1390, ceralasertib, saruparib and consolidation durvalumab (CONCORDE) phase Ib platform study of novel DNA damage response inhibitor (DDRi) agents in combination with radiotherapy in non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Greystoke, Alastair
Oughton, Jamie B.
Brown, Sarah R.
Butterworth, Karl
Coyle, Victoria
Franks, Kevin
Hassani, Adam
Harrow, Stephen
Hatton, Matthew
Hiley, Crispin T.
Kendall, Jessica
Phillip, Rachel
Norris, Matthew
Ojo, Oluwaseun
Shaw, Paul
Walker, Fiona
Yang, Huiqi
Chalmers, Anthony J.
Faivre-Finn, Corinne
机构：
[1] Univ Newcastle, Northern Ctr Canc Care, Newcastle Upon Tyne, England
[2] Univ Leeds, Leeds Inst Clin Trials Res, Leeds, England
[3] Queens Univ Belfast, Belfast, North Ireland
[4] Leeds Teaching Hosp NHS Trust, Leeds, England
[5] Northern Ctr Canc Care, Newcastle Upon Tyne, England
[6] Edinburgh Canc Ctr, Western Gen Hosp, Edinburgh, Scotland
[7] Weston Pk Hosp, Sheffield, England
[8] Univ Coll Hosp London, London, England
[9] AstraZeneca, Cambridge, England
[10] Velindre Canc Ctr, Cardiff, Wales
[11] Cambridge Univ Hosp, Cambridge, England
[12] Univ Glasgow, Glasgow, Scotland
[13] Christie NHS Fdn Trust, Manchester, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8119
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Biomarker based phase I study of Apricoxib, a potent COX-2 inhibitor in combination with erlotinib in non-small cell lung cancer (NSCLC) patients
    Reckamp, Karen
    Patel, Ravi
    Gitlitz, Barbara
    Chen, Lin
    Jezior, Deborah
    Zaknoen, Sara
    CANCER RESEARCH, 2009, 69
  • [22] INTERIM RESULTS FROM A PHASE IB, FIRST-IN-HUMAN STUDY OF A NOVEL COMPLEMENT FACTOR H INHIBITOR (GT103) IN PATIENTS WITH REFRACTORY NON-SMALL CELL LUNG CANCER (NSCLC)
    Clarke, Jeffrey
    Stinchcombe, Thomas
    Crawford, Jeffrey
    Mamdani, Hirva
    Gu, Lin
    Ready, Neal
    Nixon, Andrew
    Baleviic, Stephen
    Campa, Michael
    Gottlin, Liz
    Bushey, Ryan
    Herndon, James
    Antonia, Scott
    Patz, Edward
    Simon, George
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A730 - A730
  • [23] Final Overall Results of a Study with a Novel Triplet Induction Chemotherapy Regimen (PACCAGE) Followed by Consolidation Radiotherapy in Locally Advanced Inoperable Non-small Cell Lung Cancer (NSCLC)
    Schallier, Denis
    Bral, Samuel
    Ilsen, Bart
    Neyns, Bart
    Fontaine, Christel
    Decoster, Lore
    De Mey, Johan
    Meysman, Marc
    De Greve, Jacques
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (06) : 728 - 735
  • [24] Phase I study of daily oral AZD 2171, an inhibitor of the vascular endothelial growth factor receptor (VEGFR), in combination with carboplatin/paclitaxel in patients with advanced non-small cell lung cancer (NSCLC): A study of the NCICCTG.
    Laurie, SA
    Arnold, A
    Gauthier, I
    Ellis, P
    Goss, G
    Chen, E
    Shepherd, F
    Fisher, B
    Robertson, J
    Seymour, L
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 8970S - 8970S
  • [25] A phase lilt and pharmacokinetic study of BGB324, a selective AXL inhibitor as monotherapy and in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC)
    Byers, L.
    Gerber, D.
    Peguero, J.
    Micklem, D.
    Yule, M.
    Lorens, J. B.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S18 - S19
  • [26] Phase IB study of olaparib (AZD2281) plus gefitinib in EGFR-mutant patients (p) with advanced non-small-cell lung cancer (NSCLC) (NCT01513174/GECP-GOAL).
    Garcia Campelo, Rosario
    Felip, Enriqueta
    Massuti, Bartomeu
    Majem, Margarita
    Carcereny, Enric
    Cardenal, Felipe
    Angel Molina-Vila, Miguel
    Martinez Marti, Alex
    Luis Marti-Ciriquian, Juan
    Alonso-Jaudenes Curbera, Guillermo
    Pallares, Cinta
    Palmero, Ramon
    Carmen Gonzalez-Arenas, Maria
    Mayo-de las Casas, Clara
    Sanchez-Ronco, Maria
    Rosell, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [27] Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer
    Wu, Trudy C.
    Stube, Annalise
    Felix, Carol
    Oseguera, Denise
    Romero, Tahmineh
    Goldman, Jonathan
    Garon, Edward B.
    Lee, Jay M.
    Glaspy, John
    Lisberg, Aaron E.
    Rusthoven, Chad G.
    Camidge, D. Ross
    Siva, Shankar
    Solomon, Benjamin
    Lee, Alan
    Tenn, Stephen E.
    Shaverdian, Narek
    Steinberg, Michael L.
    Raldow, Ann C.
    Lee, Percy
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (01): : 118 - 122
  • [28] CLINICAL ACTIVITY OF LURBINECTEDIN (PM01183) IN COMBINATION WITH GEMCITABINE (GEM) IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS): PRELIMINARY SUBGROUP ANALYSIS OF A PHASE IB STUDY
    Paz-Ares, Luis
    Calvo, E.
    Forster, M.
    Boni, V.
    Lopez Calderero, I.
    Benafif, S.
    Kahatt, C.
    Turnbull, S.
    Corral, J.
    Cubillo, A.
    Flynn, M.
    Luque Ibanez, M.
    Soto Matos-Pita, A.
    Szyldergemajn, S.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S569 - S569
  • [29] PARIS: A phase I study of pembrolizumab anti-PD-1 monoclonal antibody in combination with radiotherapy (RT) in locally advanced non-small cell lung cancer (NSCLC)
    Kordbacheh, T.
    Chan, C.
    Bossons, A.
    Franks, K.
    McDonald, F.
    Forster, M.
    Mendes, R.
    Quezada, S.
    Dovedi, S.
    Ralph, C.
    Popat, S.
    Harrington, K.
    Melcher, A.
    Popple, A.
    Illidge, T.
    Faivre-Finn, C.
    LUNG CANCER, 2017, 103 : S75 - S76
  • [30] Phase II study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced non-small cell lung cancer (NSCLC)
    Spira, A. I.
    Iannotti, N. O.
    Savin, M. A.
    Neubauer, M.
    Gabrail, N. Y.
    Yanagihara, R.
    Datta, K. K.
    Zang, E. A.
    Fields, S. Z.
    Das, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345